Natco Pharma Limited announced that its wholly-owned subsidiary, NATCO Pharma Asia Pte. Ltd., incorporated in Singapore, has acquired the remaining 49% shareholding in PT NATCO Lotus Farma from PT Lotus Farma Indonesia. Previously, NATCO held a 51% stake in the Indonesian entity. Following this acquisition, NATCO, along with its subsidiary, now wholly owns 100% of PT NATCO Lotus Farma. The acquisition was a cash consideration amounting to IDR 14,075,400,000, which is approximately ₹7.7 crore. The target entity, PT NATCO Lotus Farma, operates in the Pharmaceuticals industry and was incorporated on August 28, 2023. Its turnover for the year-to-date September 2025 was IDR 5,073 million (approximately ₹2.7 crore), and for April-March 2025, it was IDR 3,324 million (approximately ₹1.6 crore). No turnover was reported for the fiscal years April-March 2024 and April-March 2023. The acquisition's objective is to achieve full ownership of the Indonesian subsidiary, and it has already been completed with no governmental or regulatory approvals required.
